BRIEF-Myriad’s provides data on prostate cancer test
February 17, 2017 at 07:30 AM EST
* Myriad’s Prolaris® Test significantly improves the risk classification for one third of men diagnosed with localized prostate cancer Source text for Eikon: Further company coverage:
